An Open Label, Partially Randomized, Four-period Study in Healthy Male Subjects to Investigate the Bioavailability and Pharmacokinetics of a Single Dose of AZD7594 When Administered Intravenously, Orally and Inhaled Via Two Different Dry Powder Inhalers (DPI) and a Pressurized Metered-dose Inhaler (pMDI)
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs AZD 7594 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 20 Jun 2016 Status changed from active, no longer recruiting to completed.
- 15 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.
- 15 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2016.